The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Angioedema (may cause UAO, asphyxia and death)
Publications
Angioedema associated with aspirin and rofecoxib.
The Annals of pharmacotherapy. 2005;39(5):944-8
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2005;94(1):34-8
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.
British journal of clinical pharmacology. 2003;55(2):166-74
Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib.
Postgraduate medical journal. 2002;78(921):439-40